You are here

6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria

Last updated on December 17, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Red Deer, Alberta, T4N 6V7 Canada
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Diabetic Nephropathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
31+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female outpatients 31 years of age or older.

- Females must no longer be of child-bearing potential, must have a negative serum
pregnancy test, and cannot be breast-feeding.

- Non-vasectomized male must be willing to abstain from sexual intercourse or willing to
use a condom in addition to having their female partner use another form of
contraception.

- Diagnosis of probable Type 2 diabetes after the age of 30 and for at least 6 months
prior to the screening visit and: not requiring insulin within first year of
diagnosis; no history of diabetic ketoacidosis (DKA); body mass index (BMI) of 40 or
less at the screening visit

- Presence of persistent albuminuria with a UACR of 6.7 - 203 mg/mmol Must be taking the
highest tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an
angiotensin II receptor blocker (ARB) and have been maintained on that dose for at
least 3 months prior to the Baseline visit

- Blood pressure(BP) must be stable and well controlled by the judgement of the
investigator (goal of the control of BP is 130/80 or less). If required, the use of
anti-hypertensives in addition to an ACE inhibitor or an ARB is acceptable.

- Patients with a calculated creatinine clearance of greater than or equal to 30 mL/min
and without the presence of clinically significant hematuria or red or white cell
casts can be included in the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Diagnosis of Type 1 diabetes

- Hemoglobin A1c (HbA1c) >10%

- Females cannot be breast-feeding

- Known renal artery stenosis

- Calculated creatinine clearance hematuria of red or white cell casts

- Chronic use of NSAIDs or more than 1 g/day of aspirin

- QTc >450 msec for females or >430 msec for males (a measure of the time between the
start of the Q wave and the end of the T wave in the heart's electrical cycle)

- Known family history of prolonged QT syndrome

- History of symptomatic congestive heart failure within the last 2 years

- History of syncope in the lst 2 years or recurrent hypokalemia, including that caused
by diuretics

- Myocardial infarction or signs or symptoms of unstable coronary artery disease with
the last year

- Pulmonary disease or evidence of clinically significant pulmonary symptoms.

- Active neoplastic disease. (Excised cutaneous basal cell carcinomas are not excluded).
Patients with stable prostate cancer may be included at the discretion of the Medical
Monitor.

- Any clinically significant hematologic or coagulation disorder

- Any clinically significant hepatic disease

- Use of excluded medications: drugs known to significantly increase QTc and/or have
increased risk of torsades de point, immunosuppressive agents, cancer chemotherapeutic
agents, oral corticosteroids other than maintenance doses equivalent to 7.5 mg
prednisone per day, and radiotherapy

- Use of an investigational drug within 30 days or within 5 half-lives of the
investigational agent, whichever is longer, or use of an investigational medical
device within 2 weeks before or after the study

- Any other disease or condition that, in the opinion of the investigator, makes the
patient unsuitable to participate in this study

NCT00287183
Pfizer
Completed
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488 to patients with diabetic nephropathy.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Diabetic Nephropathy
  • Drug: PF-04494700 (TTP488)
    60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
  • Other: Placebo
    Placebo
  • Active Comparator: PF-04494700 (TTP488)
    Intervention: Drug: PF-04494700 (TTP488)
  • Placebo Comparator: Placebo
    Intervention: Other: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
110
August 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female outpatients 31 years of age or older.
  • Females must no longer be of child-bearing potential, must have a negative serum pregnancy test, and cannot be breast-feeding.
  • Non-vasectomized male must be willing to abstain from sexual intercourse or willing to use a condom in addition to having their female partner use another form of contraception.
  • Diagnosis of probable Type 2 diabetes after the age of 30 and for at least 6 months prior to the screening visit and: not requiring insulin within first year of diagnosis; no history of diabetic ketoacidosis (DKA); body mass index (BMI) of 40 or less at the screening visit
  • Presence of persistent albuminuria with a UACR of 6.7 - 203 mg/mmol Must be taking the highest tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and have been maintained on that dose for at least 3 months prior to the Baseline visit
  • Blood pressure(BP) must be stable and well controlled by the judgement of the investigator (goal of the control of BP is 130/80 or less). If required, the use of anti-hypertensives in addition to an ACE inhibitor or an ARB is acceptable.
  • Patients with a calculated creatinine clearance of greater than or equal to 30 mL/min and without the presence of clinically significant hematuria or red or white cell casts can be included in the study.

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes
  • Hemoglobin A1c (HbA1c) >10%
  • Females cannot be breast-feeding
  • Known renal artery stenosis
  • Calculated creatinine clearance <30 mL/min or the presence of clinically significant hematuria of red or white cell casts
  • Chronic use of NSAIDs or more than 1 g/day of aspirin
  • QTc >450 msec for females or >430 msec for males (a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle)
  • Known family history of prolonged QT syndrome
  • History of symptomatic congestive heart failure within the last 2 years
  • History of syncope in the lst 2 years or recurrent hypokalemia, including that caused by diuretics
  • Myocardial infarction or signs or symptoms of unstable coronary artery disease with the last year
  • Pulmonary disease or evidence of clinically significant pulmonary symptoms.
  • Active neoplastic disease. (Excised cutaneous basal cell carcinomas are not excluded). Patients with stable prostate cancer may be included at the discretion of the Medical Monitor.
  • Any clinically significant hematologic or coagulation disorder
  • Any clinically significant hepatic disease
  • Use of excluded medications: drugs known to significantly increase QTc and/or have increased risk of torsades de point, immunosuppressive agents, cancer chemotherapeutic agents, oral corticosteroids other than maintenance doses equivalent to 7.5 mg prednisone per day, and radiotherapy
  • Use of an investigational drug within 30 days or within 5 half-lives of the investigational agent, whichever is longer, or use of an investigational medical device within 2 weeks before or after the study
  • Any other disease or condition that, in the opinion of the investigator, makes the patient unsuitable to participate in this study
Sexes Eligible for Study: All
31 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00287183
B0341001
TTP488-202
No
Not Provided
Not Provided
Director, Clinical Trials Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now